A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques

(2019) Huihui Chong et al.   PLoS Pathogens

Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

(2018) Huihui Chong et al.   JOURNAL OF VIROLOGY

Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes

(2018) Longlong Si et al.   Science Advances

Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein

(2017) Javier Guenaga et al.   IMMUNITY

Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains

(2017) Qianqian Qi et al.   JOURNAL OF INFECTION

Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus

(2017) Wenqian Yang et al.   MICROBES AND INFECTION

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

(2017) Shan Su et al.   MOLECULES

Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation

(2017) Jinhwan Cho et al.   Scientific Reports

Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors

(2016) Shan Su et al.   JOURNAL OF VIROLOGY

An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene

(2016) Zhiwu Sun et al.   Emerging Microbes & Infections

Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket

(2015) Yang Su et al.   JOURNAL OF VIROLOGY

Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy

(2015) Qian Wang et al.   JOURNAL OF VIROLOGY

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy

(2015) Xiaojie Zhu et al.   Scientific Reports

Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure

(2014) M. T. Augusto et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats

(2012) Xiaoguang Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain

(2012) Lu Lu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1

(2012) Avraham Ashkenazi et al.   FASEB JOURNAL

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor

(2012) Huihui Chong et al.   PLoS One

Multifaceted action of Fuzeon as virus–cell membrane fusion inhibitor

(2011) Avraham Ashkenazi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function

(2011) D. Eggink et al.   JOURNAL OF VIROLOGY

Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain

(2010) Yael Wexler-Cohen et al.   FASEB JOURNAL

An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life

(2009) D. Xie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B

(2009) Khalid Abu Ajaj et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

(2009) P. Ingallinella et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Membrane-Anchored HIV-1 N-Heptad Repeat Peptides Are Highly Potent Cell Fusion Inhibitors via an Altered Mode of Action

(2009) Yael Wexler-Cohen et al.   PLoS Pathogens